164 related articles for article (PubMed ID: 24075093)
21. Influence of the sorafenib patients assistance program on treatment compliance and overall survival of unresectable hepatocellular carcinoma patients.
Lesmana LA; Gani RA; Hasan I; Waspodo A; Boedi P; Luwia MS; Ganggaiswari A
Acta Med Indones; 2012 Jul; 44(3):228-32. PubMed ID: 22983078
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation.
Sotiropoulos GC; Nowak KW; Fouzas I; Vernadakis S; Kykalos S; Klein CG; Paul A
Transplant Proc; 2012 Nov; 44(9):2754-6. PubMed ID: 23146514
[TBL] [Abstract][Full Text] [Related]
23. Management of sorafenib-related adverse events: a clinician's perspective.
Brose MS; Frenette CT; Keefe SM; Stein SM
Semin Oncol; 2014 Feb; 41 Suppl 2():S1-S16. PubMed ID: 24576654
[TBL] [Abstract][Full Text] [Related]
24. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib.
Vincenzi B; Santini D; Russo A; Addeo R; Giuliani F; Montella L; Rizzo S; Venditti O; Frezza AM; Caraglia M; Colucci G; Del Prete S; Tonini G
Oncologist; 2010; 15(1):85-92. PubMed ID: 20051477
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
Miyaki D; Aikata H; Kan H; Fujino H; Urabe A; Masaki K; Fukuhara T; Kobayashi T; Naeshiro N; Nakahara T; Kawaoka T; Hiramatsu A; Takahashi S; Ishikawa M; Kakizawa H; Awai K; Chayama K
J Gastroenterol Hepatol; 2013 Dec; 28(12):1834-41. PubMed ID: 23808713
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review.
Zhang X; Yang XR; Huang XW; Wang WM; Shi RY; Xu Y; Wang Z; Qiu SJ; Fan J; Zhou J
Hepatobiliary Pancreat Dis Int; 2012 Oct; 11(5):458-66. PubMed ID: 23060390
[TBL] [Abstract][Full Text] [Related]
27. Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors.
Edeline J; Crouzet L; Le Sourd S; Larible C; Brunot A; Le Roy F; Cattenoz C; Latournerie M; Gédouin D; Guillygomarc'h A; Boucher E
Cancer Chemother Pharmacol; 2015 Jan; 75(1):215-9. PubMed ID: 25477009
[TBL] [Abstract][Full Text] [Related]
28. Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma.
Williet N; Clavel L; Bourmaud A; Verot C; Bouarioua N; Roblin X; Merle P; Phelip JM
Dig Liver Dis; 2017 Sep; 49(9):1043-1049. PubMed ID: 28712860
[TBL] [Abstract][Full Text] [Related]
29. Meta-analysis of the efficacy of sorafenib for hepatocellular carcinoma.
Wang Z; Wu XL; Zeng WZ; Xu GS; Xu H; Weng M; Hou JN; Jiang MD
Asian Pac J Cancer Prev; 2013; 14(2):691-4. PubMed ID: 23621220
[TBL] [Abstract][Full Text] [Related]
30. Long-term therapy with sorafenib is associated with pancreatic atrophy.
Xu L; Zhou DS; Zhao J; Spolverato G; Zhang YJ; Li SP; Chen MS; Pawlik TM
J Surg Res; 2015 Dec; 199(2):314-21. PubMed ID: 26115806
[TBL] [Abstract][Full Text] [Related]
31. Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group.
Casadei Gardini A; Scarpi E; Marisi G; Foschi FG; Donati G; Giampalma E; Faloppi L; Scartozzi M; Silvestris N; Bisulli M; Corbelli J; Gardini A; La Barba G; Veneroni L; Tamberi S; Cascinu S; Frassineti GL
Oncotarget; 2016 Mar; 7(12):15243-51. PubMed ID: 26893366
[TBL] [Abstract][Full Text] [Related]
32. Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma.
Chen SW; Lin LC; Kuo YC; Liang JA; Kuo CC; Chiou JF
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1041-7. PubMed ID: 24661657
[TBL] [Abstract][Full Text] [Related]
33. Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability.
Køstner AH; Sorensen M; Olesen RK; Grønbæk H; Lassen U; Ladekarl M
ScientificWorldJournal; 2013; 2013():931972. PubMed ID: 23431262
[TBL] [Abstract][Full Text] [Related]
34. Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
Fukudo M; Ito T; Mizuno T; Shinsako K; Hatano E; Uemoto S; Kamba T; Yamasaki T; Ogawa O; Seno H; Chiba T; Matsubara K
Clin Pharmacokinet; 2014 Feb; 53(2):185-96. PubMed ID: 24135988
[TBL] [Abstract][Full Text] [Related]
35. Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib.
Lamarca A; Abdel-Rahman O; Salu I; McNamara MG; Valle JW; Hubner RA
Clin Transl Oncol; 2017 Mar; 19(3):364-372. PubMed ID: 27541594
[TBL] [Abstract][Full Text] [Related]
36. Biomarkers of apoptosis and necrosis in patients with hepatocellular carcinoma treated with sorafenib.
Godin C; Louandre C; Bodeau S; Diouf M; Saidak Z; Conte MA; Chauffert B; Barbare JC; Barget N; Trinchet JC; Ganne N; Galmiche A
Anticancer Res; 2015 Mar; 35(3):1803-8. PubMed ID: 25750346
[TBL] [Abstract][Full Text] [Related]
37. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
Weintraub JL; Salem R
J Vasc Interv Radiol; 2013 Aug; 24(8):1123-34. PubMed ID: 23562168
[TBL] [Abstract][Full Text] [Related]
38. Factors contributing to the overall survival in patients with hepatocellular carcinoma treated by sorafenib.
Tsukui Y; Mochizuki H; Hoshino Y; Kawakami S; Kuno T; Fukasawa Y; Iwamoto F; Hirose S; Yoshida T; Hosoda K; Suzuki Y; Hosoda K; Kojima Y; Hirose Y; Shindou K; Matsuda M; Yagawa S; Tawara A; Kobayashi M; Konishi T; Yamazaki T; Takahashi S; Fuji H; Enomoto N; Omata M
Hepatogastroenterology; 2012; 59(120):2536-9. PubMed ID: 22497953
[TBL] [Abstract][Full Text] [Related]
39. Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit.
D'Angelo S; Secondulfo M; De Cristofano R; Sorrentino P
Future Oncol; 2013 Apr; 9(4):485-91. PubMed ID: 23560372
[TBL] [Abstract][Full Text] [Related]
40. Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib.
Ganten MK; Schuessler M; Bruckner T; Ganten TM; Koschny R
Oncology; 2015; 89(2):88-94. PubMed ID: 25871578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
